Abstract: A method of inhibiting sleep apnea is disclosed comprising administering an effective amount of 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidine-L-prolinamide or a pharmaceutically acceptable acid addition salt thereof.

Abstract: A cell-proliferation promoting and wound-healing composition and method utilizing a compound or salt of Formula (I), ##STR1## in which R.sub.1 is (CH.sub.2).sub.n CH.sub.3 wherein n is 0 to about 10; Formula (II), ##STR2## in which R is NH(CH.sub.2).sub.a CH.sub.3 or O(CH.sub.2).sub.a CH.sub.

Abstract: A composition comprising a trivalent bismuth salt, particularly bismuth nitrate, and dimercaprol is described. Methods for using the composition as a bacteriocidal and bacteriostatic agent and as a disinfectant and preservative are also provided.

Abstract: Prevention or treatment of low renin hypertension by administration of an endothelin antagonist is disclosed.

Abstract: A method for the treatment of acne is provided which results in the reduction of vestibular side effects following administration of oral tetracycline antibiotics.

Abstract: A topical pharmaceutical composition having penetration enhancing properties for treating fungal dermatological conditions, comprising a pharmaceutically active topical antifungal agent selected from sulconazole and naftifine with an acetate penetration enhancing compound is disclosed.

Abstract: Nefazodone and its pharmaceutically acceptable salts are useful in prophylactic treatment of recurrent headache disorders, as, in particular, vascular and migraine headaches.

Abstract: Described are the use of compounds of Formula (I) depicted below, as active principals for treating skin conditions and compositions containing these compounds, ##STR1## where R.sub.4 is (CR.sub.5 R.sub.6 --CR.sub.7 R.sub.8 --X.sub.1).sub.n --CR.sub.9 R.sub.10 R.sub.11 ; n is an integer from 1 to 18; R.sub.1, R.sub.2, R.sub.3, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11 are, independently, hydrogen or substituents selected from alkyls, alkenyls, oxa-alkyls, aralkyls and aryls; and X, X.sub.1, Y and Z are, independently, oxygen.

Abstract: A method and pharmaceutical compositions are disclosed for reducing oxidative degradation of 17 .alpha.-ethinylestradiol comprising combining the estradiol with an effective amount of cyclodextrin, thus forming a cyclodextrin clathrate of the steroid.

Abstract: An injection solution comprising a 2-[(2-pyridyl)methylsulfinyl]-benzimidazole compound or a salt thereof having antiulcer activity and an aqueous solvent added with no nonaqueous solvent is disclosed wherein the pH is not less than 9.5 and not more than 11.5.

Abstract: 5-Aryl isoxazole derivatives of formula (I): ##STR1## wherein: Ar represents phenyl optionally substituted substituted by one or more groups R.sup.2 ;R represents hydrogen, --CO.sub.2 R.sup.3, --COR.sup.4, cyano, halogen, alkyl or haloalkyl;R.sup.1 represents alkyl, haloalkyl or cycloalkyl;R.sup.2 represents a halogen atom, R.sup.4, nitro, --CO.sub.2 R.sup.3, --OR.sup.4, --S(O).sub.m R.sup.4, --S(O).sub.m R.sup.5, --O--(CH.sub.2).sub.p --OR.sup.4 or an alkyl group substituted by --OR.sup.4 ;R.sup.3 and R.sup.4, which may be the same or different, each represent alkyl or haloalkyl;R.sup.5 represents optionally substituted phenyl;p represents an integer from 1 to 3; andm represents zero, 1 or 2;the herbicidal properties of these derivatives and their application to crop protection is described.

Abstract: The compounds of the present invention are deoxy disubstituted or dideoxy disubstituted derivatives of .alpha.-D-mannofuranoside and .beta.-L-gulofuranoside hexoses which exhibit anti-inflammatory and anti-proliferative activity. Pharmaceutical compositions containing the compounds and methods of treating inflammatory and/or autoimmune disorders employing the compounds are disclosed.

Abstract: Quinophthalone derivatives of the formula I ##STR1## where the group A completes substituted or unsubstituted heteroaromatic rings and the group B completes a substituted or unsubstituted aromatic ring, are prepared by reacting a methyl-substituted heterocyclic compound of the formula II ##STR2## with an anhydride of an aromatic dicarboxylic acid of the formula III ##STR3## or the corresponding free dicarboxylic acid (IIIa) in the presence of an acid and of an organic solvent, the organic solvent used being an alkyl benzoate.

Abstract: The invention relates to N-sulfonyl derivatives of formulae (I)" and (I)' ##STR1## and to pharmaceutical compositions in which they are present. The compounds have an affinity for the vasopressin and ocytocin receptors.

Abstract: Piperidylmethyl-substituted chroman derivatives can be prepared by first reducing corresponding chromancarboxylic acid derivatives, if appropriate with prior activation, with the cyclic amines and then reducing the carbonyl group, or by reacting chromanmethyl compounds directly with the cyclic amines. The substituted piperidylmethyl-substituted chroman derivatives can be employed as active compounds in medicaments, in particular for the treatment of diseases of the central-nervous system.

Abstract: Compositions comprising emedastine and aliphatic monocarboxylic acid lower alkyl esters or aliphatic dicarboxylic acid di-lower alkyl esters for percutaneous administration are presented.

Abstract: The invention provides compounds of formula (I): ##STR1## or a physiologically acceptable salt, solvate or metabolically labile ester thereof whereinR.sup.1 represents a hydrogen atom or a halogen atom or a group selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, fluoroC.sub.1-6 alkyl, C.sub.1-6 alkoxy, --CHO, --CO.sub.2 H or --COR.sup.2 ;Ar represents optionally substituted phenylHet represents the group ##STR2## A represents ##STR3## The compounds may be used in the treatment or prophylaxis of hypertension and diseases associated with cognitive disorders.

Abstract: Methods of inhibiting cell proliferation in a patient suffering from such disorder comprising the use of a styryl-substituted heteroaryl compound wherein the heteroaryl group is a monocyclic ring with 1 or 2 heteroatoms, or a bicyclic ring with 1 to about 4 heteroatoms, said compound optionally substituted or polysubstituted, with the proviso that when said ring is polysubstituted, the substituents do not have a common point of attachment to said ring, and those compounds wherein no substituent on the heteroaryl group is a carboxy group or an ester group, and pharmaceutical compositions comprising such compounds.

Abstract: Compounds characterized generally as pyridinyl-terminated alkylamino ethynyl alanine amino diol derivatives are useful as renin inhibitors for the treatment of hypertension. Compounds of particular interest are those of Formula I ##STR1## wherein A is selected from CO and SO.sub.2 ; wherein X is selected from oxygen atom and methylene; wherein G is a pyridinyl group; wherein R.sub.1 is selected from hydrido, methyl, ethyl, isopropyl and n-propyl; wherein R.sub.2 is phenylmethyl; wherein each of R.sub.3 and R.sub.5 is hydrido; wherein R.sub.4 is selected from ##STR2## wherein V is selected from hydrido and methyl; wherein R.sub.6 is cyclohexylmethyl; wherein R.sub.7 is selected from isobutyl, cyclopropyl and cyclopropylmethyl; wherein q is a number selected from zero through three, inclusive; and wherein n is a number selected from zero through three, inclusive; or a pharmaceutically-acceptable salt thereof.

Abstract: Sulfonamide derivatives of the general formula (I): ##STR1## wherein preferably R.sup.1 represents a lower alkoxy group, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are as defined in the specification, A and B may be the same or different from each other and each represents .dbd.N-- or .dbd.CH--, E represents an aromatic 6-membered cyclic group, which may have 1 or 2 nitrogen atoms in the ring, and may be substituted with 1 to 3 substituents which may be the same or different from one another with the proviso that a combination of R.sup.1 which is a hydrogen atom, lower alkyl group, nitro group or amino group which may be protected, R.sup.2 and R.sup.3 which are each a hydrogen atom, A and B which are each .dbd.CH-- and E which is a phenyl group which may be substituted with 1 to 3 substituents G which may be the same or different from one another is excluded, or pharmacologically acceptance salts of them.